There are many important figures in the cancer-research community. Some of the most brightest of minds can be found here. Dr. Clay Siegall just so happens to be one of those bright minds, and he is seemingly leaving a lasting impact on this genre. Dr. Siegall is very ambitious on what he wants to achieve despite having a humble appearance. He is considered to be an old-guard of cancer research, especially when being compared to many of his counterparts. This is a good thing because he uses tried and true techniques to find solutions. Medicine and technology now seems to go hand-to-hand and Dr. Siegall is at the forefront of this progressive movement.
Dr. Siegall founded a biotech-oncology back in 1998. This biotech-oncology company’s name is Seattle Genetics. This company is a worldwide leader in developing some of the best cancer-fighting medications. It earns billions of dollars on an annual basis and over the last five years, the company’s stock has nearly tripled. Seattle Genetics generated income from a variety of ways. This includes generating income from:
- Selling its own proprietary drugs
- Through Production Partnerships
- The licensing of its own technologies
Dr. Siegall has worked for numerous prominent names in this industry, but he also noticed that patents were a very important part of the game. “I would be lying if I said that money wasn’t involved in bringing me to this field of work,” said Siegall. Though he was a senior researcher with Bristol Myers Squibb, Dr. Siegall was only earning a good paycheck. By controlling and owning the patents, you’ll get to reap the rewards of bigger paychecks. This is the route that he chose to take, and this route plays a major reason to why the company is so successful.